On April 1, 2020 Legend Biotech Corporation (Legend), a global, clinical-stage biopharmaceutical company engaged in the discovery and development of novel cell therapies for oncology and other indications, reported that it has raised $150.5 million in Series A financing (Press release, Legend Biotech, APR 1, 2020, View Source [SID1234556095]). Proceeds from the financing will be used to advance the research and development and commercialization of Legend’s pipeline programs and expansion of manufacturing facilities, enhancement of its research and development platform, as well as general corporate expenses.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

New investors included Hudson Bay Capital Management LP, Johnson & Johnson Innovation-JJDC, Inc., Lilly Asia Ventures, Vivo Capital, RA Capital Management and other large, reputable institutional investor.

Morgan Stanley Asia Limited and Jefferies Hong Kong Limited advised Legend in this transaction.